ClinicalTrials.Veeva

Menu
K

Kyiv City Clinical Oncology Center | Kyiv, Ukraine

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Cisplatin
MK-6482
MK-3475-992
MK-3475-866
Enfortumab
MK-3475-905
Docetaxel
Enobosarm
Tamibarotene

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 12 total trials

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Cr...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Everolimus
Drug: Belzutifan

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenv...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Belzutifan
Biological: Pembrolizumab/Quavonlimab

Researchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of cancer that has not spread from the muscles in...

Enrolling
Urinary Bladder Neoplasms
Radiation: Conventional Radiotherapy (Bladder and pelvic nodes)
Drug: Pembrolizumab

This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible o...

Active, not recruiting
Urinary Bladder Cancer, Muscle-invasive
Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Drug: Pembrolizumab

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible pat...

Active, not recruiting
Bladder Cancer
Drug: Placebo
Drug: Pembrolizumab

Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung...

Active, not recruiting
Small Cell Lung Cancer
Drug: Platinum, investigator's choice
Biological: Pembrolizumab 400 mg

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) tr...

Active, not recruiting
Gastroesophageal Junction Cancer
Gastric Cancer
Drug: Capecitabine
Drug: Oxaliplatin

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by eit...

Active, not recruiting
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Drug: Cisplatin
Biological: Pembrolizumab

Trial sponsors

Merck Sharp & Dohme (MSD) logo
B
C
Incyte logo
Veru logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems